For your patients with ADHD who are 6 years and older
Quillivant XR® delivers
Patients' response to medications can vary.
With Quillivant XR®, drug release is not affected by methylphenidate metabolism, food timing or type, location of release in the GI tract, or pH of the GI tract.2,3
Eligible patients may PAY $25
Learn more about Savings & SupportUnique technology provides continuous delivery of methylphenidate through the day2
• Predictable symptom control from patient to patient4
Durable efficacy 12
hours postdose
Consistent PK profile with
no additional peak or crash
Microtitration
with a liquid
ADHD, Attention Deficit Hyperactivity Disorder; ER, extended-release; PK, pharmacokinetic.
* This is based on information licensed from IQVIA®: Xponent ADHD market data for the period of Jan 2023–June 2023 reflecting estimates of real-world activity. All rights reserved.
References: 1. Data on file. Tris Pharma, Inc., Monmouth Junction, NJ. 2. Kando JC, King TR, Pardo A. A novel, modified-release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at: American Psychiatric Association Annual Meeting; May 1-3, 2021. 3. Powell JJ, Greenfield SM, Thompson RP. Concentrations of metals in gastric juice in health and peptic ulcer disease. Gut. 1992;33(12):1617-1620. 4. Wigal SB, Childress A, Berry SA, et al. Efficacy and safety of a chewable methylphenidate extended-release tablet in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):690-699.